Abstract
Purpose: Antiphospholipid syndrome (APS), as an acquired prothrombotic disorder, is increasingly being recognised as an important cause of systemic venous and arterial thrombosis. The defining feature of the condition is the presence of raised levels of antibodies to negatively charged phospholipids in the serum.
Methods: We describe 2 cases of APS with ocular involvement and review the recent literature. Both patients experienced acute visual loss. It was the presenting symptom in one case - a finding that led to the diagnosis of the syndrome.
Results: Management with anticoagulation therapy, in which the International Normalised Ratio (INR) has been maintained at or above 3, resulted in reperfusion of the ischaemic retina and stabilisation of the retinopathy in one patient, whilst in the other case, where the INR was less than 3, irreversible visual loss occurred.
Conclusion: Anticoagulation with warfarin appears to result in reperfusion of ischaemic retina with stabilisation of the neovascular process when the INR is greater than 3.
Similar content being viewed by others
Article PDF
References
Hughes GRV . Thrombosis, abortion, cerebral disease and the lupus anticoagulant. BMJ 1983;287:1088–9.
Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.
Levine SR, Crofts JW, Lesser GR, Floberg J, Welch KM . Visual symptoms associated with the presence of a lupus anticoagulant. Ophthalmology 1988;95:686–92.
Hartnett ME, Pruett RC, DaSilva KC, Burkart PT . Antiphospholipid antibody syndrome associated with microscotomata. Am J Ophthalmol 1994;118:397–8.
Wiechens B, Schroder JO, Potzsch B, Rochels R . Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy. Am J Ophthalmol 1997;123:848–50.
Castanon C, Amigo MC, Banales JL, Nava A, Reyes PA . Ocular vaso-occlusive disease in primary antiphospholipid syndrome. Ophthalmology 1995;102:256–62.
McKibbin M, Parulekar M, Innes JR . Recurrent retinal artery occlusion after the disappearance of lupus anticoagulant. Eye 1998;12:893–4.
Palimar P, Cota N . Asymptomatic vaso-occlusive retinopathy in Hughes’ syndrome. Eye 1998;12:320–1.
Acheson JF, Gregson RM, Merry P, Schulenburg WE . Vaso-occlusive retinopathy in the primary anti-phospholipid antibody syndrome. Eye 1991;5:48–55.
Digre KB, Durcan FJ, Branch DW, Jacobson DM, Varner MW, Baringer JR . Amaurosis fugax associated with antiphospholipid antibodies. Ann Neurol 1989;25:228–32.
Reino S, Munoz-Rodriguez FJ, Cervera R, Espinosa G, Font J, Ingelmo M . Optic neuropathy in the ‘primary’ antiphospholipid syndrome: report of a case and review of the literature. Clin Rheumatol 1997;16:629–31.
Dori D, Gelfand YA, Brenner B, Miller B . Cilioretinal artery occlusion: an ocular complication of primary antiphospholipid syndrome. Retina 1997;17:555–7.
Giordano N, Senesi M, Battisti E, et al. Antiphospholipid antibodies in patients with retinal vascular occlusions. Acta Ophthalmol Scand 1998;76:128–9.
Booth CD . A drug interaction between danazol and warfarin. Pharm J 1993;242:439–40.
Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544–7.
Roubey RA . Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other ‘antiphospholipid’ autoantibodies. Blood 1994;84:2854–67.
Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;II:1211–4.
Shi W, Krilis SA, Chong BH, S, Chesterman CN . Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust NZ J Med 1990;20:231–6.
Levine SR, Welch KM . The spectrum of neurologic disease associated with antiphospholipid antibodies: lupus anticoagulants and anticardiolipin antibodies. Arch Neurol 1987;44:876–83.
Coull BM, Goodnight SH . Antiphospholipid antibodies, prethrombotic states, and stroke. Stroke 1990;21:1370–4.
Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR . Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992;80:614–20.
Herranz MT, Rivier G, Khamashta MA, Blaser KU, Hughes GR . Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum 1994;37:568–7l.
Levine SR, Welch KMA . Cerebrovascular ischaemia associated with lupus anticoagulant. Stroke 1987;18:257–63.
Liou HH, Wang CR, Chen CJ, et al. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus 1996;5:307–12.
Harris EN, Gharavi AE, Hughes GR . Anti-phospholipid antibodies. Clin Rheum Dis 1985;11:591–609.
Graham EM, Spalton DJ, Barnard RO, Garner A, Russell RW . Cerebral and retinal vascular changes in systemic lupus erythematosus. Ophthalmology 1985;92:444–8.
Lie JT . Vasculopathy in the antiphospholipid syndrome: thrombosis or vasculitis, or both? J Rheumatol 1989;16:713–5.
Hughes GRV, Asherson RA, Khamashta MA . Antiphospholipid antibodies: their clinical significance. Topical Reviews (Arthritis and Rheumatism Council) 1990;16:1–4.
Asherson RA, Merry P, Acheson JF, Harris EN, Hughes GR . Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the ‘primary’ antiphospholipid syndrome. Ann Rheum Dis 1989;48:358–61.
Rosove MH, Brewer PM . Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303–8.
Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR . The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993–7.
Derksen RHWM, de Groot PG, Kater L, Nieuwenhuis HK . Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulation treatment. Ann Rheum Dis 1993;52:689–92.
Derksen RH, Hasselaar P, Blokzijl L, Gmelig Meyling FH, De Groot PG . Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 1988;47:364–71.
Kavanagh A . Danazol therapy in thrombocytopenia associated with the antiphospholipid antibody syndrome. Ann Intern Med 1994;121:767–8.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kent, D., Hickey-Dwyer, M. & Clark, D. Long-term follow-up of ischaemic retinopathy in the antiphospholipid syndrome with lupus-like disease. Eye 14, 313–317 (2000). https://doi.org/10.1038/eye.2000.79
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1038/eye.2000.79
Keywords
This article is cited by
-
Looking Into the Eyes of Patients with Antiphospholipid Syndrome
Clinical Reviews in Allergy & Immunology (2007)
-
Central retinal vein and ophthalmic artery occlusion in primary antiphospholipid syndrome
Eye (2004)